Method for aqueous phase oxo-synthesis of Iansoprazole

Abstract

The invention discloses a preparing method of lansuola pyrazole, which comprises the following steps: 1) selecting solvent A and water compound solvent B; allocating 2-97% solvent B and 3-98% 2-[3-methyl-4-(2,2,2-trifluoro ethyoxyl)-2-pyridine] sulfide-H-benzimidazole to prepare compound C; 2) blending 0-30% solvent D, 0-80% water and 20-100% oxidant to prepare compound E with the molar rate of oxidant and 2-[3-methyl-4-(2,2,2-trifluoro ethyoxyl)-2-pyridine] sulfide-H-benzimidazole at 0.1-10:1; 3) blending compound C and compound E under -10-50 deg.c; 4) adjusting pH value of composite solution at 5-11 through acid or alkaline; separating to obtain the product.

Description

technical field

[0001] The present invention relates to a kind of preparation method of lansoprazole, particularly relate to a kind of preparation method of aqueous phase oxidation synthesis lansoprazole. Background technique

[0002] Lansoprazole (English name: Lansoprazole, trade name AG-1749), chemical name: (±)-2[[[3-methyl-4-(2,2,2-trifluoroethoxy)- 2-Pyridyl]methyl]sulfinyl]-1H-benzimidazole is a proton pump inhibitor developed by Takeda Corporation of Japan. At the end of 1991, Takeda Corporation and French Houde Company were jointly approved to be marketed in France. It is used for twelve Short-term treatment of duodenal ulcers and reflux esophagitis. The drug is the second proton pump inhibitor on the market after omeprazole (Omeprazole). Lansoprazole is the benzimidazole derivative of replacement, has introduced trifluoroethoxyl group on the 4-position of pyridine ring (it is reported that Lansoprazole is owing to introducing fluorine in its chemical structure, t...